Elixir release new diabetes information

Elixir Pharmaceuticals Inc. has revealed fresh data about the use of ghrelin antagonism to possibly treat type 2 diabetes .
Elixir focuses primarily on developing new drugs and treatments to aid metabolic disease. In turn, their solutions can aid people with type 2 diabetes. Metabolic disease is a major contributory factor to the type 2 diabetes epidemic that is sweeping the globe.
The discovery involves a metabolic regulator called ghrelin. The hormone, which occurs naturally, stimulates the appetite and the level of food consumption. Elixir scientists presented their findings at a conference in America.
The team examined the affects of ghrelin on mice. The Chief Scientific Officer of Elixir, Peter DiStefano, said: “Ghrelin represents one of the most exciting and well-characterized targets in obesity and diabetes research today because of its central role in regulating metabolism . These preclinical data provide compelling evidence and further confirm ghrelin’s role in metabolic regulation. Importantly, our scientists have shown pharmacologic inhibition of the ghrelin receptor results in a reduction in fasting glucose levels, reduction in insulin resistance, and weight loss .”